European Pharmaceutical Review

JUNE 24, 2022

But what are the key potential changes and how could they impact drug developers and manufacturers? He noted that within the proposals, there is likely to be a differentiation in incentives for drug development in the orphan and unmet medical need areas. Key areas of potential legislative change. Future outlook.

Compounding 105

Compounding Drug Development Drug Pricing Dosage 105

Pharmaceutical Technology

FEBRUARY 13, 2023

The first concept for a PROTAC was published in 2001, and recently these protein degraders have gained rapid momentum as a promising novel modality. This makes early R&D less risky, as many lead compounds are discontinued due to inadequate pharmacokinetic profiles and require excessively high dosages to be pharmaceutically active.

Dosage 59

Dosage Chemotherapy Compounding Immunization 59

PharmaShots

FEBRUARY 21, 2023

Market Cap: $29.30M Founded Year: 2001 Total Employees: ~20 Headquarters: Tokyo, Japan Stock Exchange: TYO Perseus Proteomics is a Japanese biotech company focused on developing antibodies by utilizing antibody technology to provide treatment options to patients worldwide.

Dosage 56

Dosage Labelling Immunization Immunity 56

Pharmaceutical Technology

FEBRUARY 23, 2023

Biopharmaceutics is a scientific discipline that examines the interrelationship of the physicochemical properties of the drug, the dosage form in which the drug is given, and the route of administration on the rate and extent of systemic drug absorption ( Applied Biopharmaceutics and Pharmacokinetics, Shargel, Wu-Pong and Yu, 5th Edition ).

Drug Development 98

Drug Development Compounding Dosage Packaging 98